The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

por Wu, Chung-Pu, Li, Yan-Qing, Chi, Ya-Chen, Huang, Yang-Hui, Hung, Tai-Ho, Wu, Yu-Shan
Publicado 2021

The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

por Wu, Chung-Pu, Lusvarghi, Sabrina, Wang, Jyun-Cheng, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Tai-Ho, Ambudkar, Suresh V.
Publicado 2019

Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport

por Wu, Chung-Pu, Murakami, Megumi, Li, Yen-Ching, Huang, Yang-Hui, Chang, Yu-Tzu, Hung, Tai-Ho, Wu, Yu-Shan, Ambudkar, Suresh V.
Publicado 2023

Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents

por Wu, Chung-Pu, Murakami, Megumi, Wu, Yu-Shan, Chi, Ya-Chen, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Tai-Ho, Ambudkar, Suresh V.
Publicado 2021

Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells

por Li, Yan-Qing, Murakami, Megumi, Huang, Yang-Hui, Hung, Tai-Ho, Wang, Shun-Ping, Wu, Yu-Shan, Ambudkar, Suresh V., Wu, Chung-Pu
Publicado 2022

Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs

por Wu, Chung-Pu, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Lang-Cheng, Yu, Yi-Jou, Chang, Yu-Tzu, Hung, Tai-Ho, Wu, Yu-Shan
Publicado 2020

Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat

por Wu, Chung-Pu, Hung, Cheng-Yu, Lusvarghi, Sabrina, Chang, Yen-Fu, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Tai-Ho, Yu, Jau-Song, Ambudkar, Suresh. V.
Publicado 2021

P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells

por Wu, Chung-Pu, Hung, Cheng-Yu, Murakami, Megumi, Wu, Yu-Shan, Lin, Chun-Ling, Huang, Yang-Hui, Hung, Tai-Ho, Yu, Jau-Song, Ambudkar, Suresh V.
Publicado 2022

Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

por Wu, Chung-Pu, Hung, Tai-Ho, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Lang-Cheng, Yu, Yi-Jou, Chang, Yu-Tzu, Wang, Shun-Ping, Wu, Yu-Shan
Publicado 2020

ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines

por Wu, Chung-Pu, Hung, Cheng-Yu, Hsieh, Ya-Ju, Murakami, Megumi, Huang, Yang-Hui, Su, Tsung-Yao, Hung, Tai-Ho, Yu, Jau-Song, Wu, Yu-Shan, Ambudkar, Suresh V.
Publicado 2023

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells

por Wu, Chung-Pu, Li, Yen-Ching, Murakami, Megumi, Hsiao, Sung-Han, Lee, Yun-Chieh, Huang, Yang-Hui, Chang, Yu-Tzu, Hung, Tai-Ho, Wu, Yu-Shan, Ambudkar, Suresh V.
Publicado 2023